Pedersen COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 ...

NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...